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Tbjective: Intimal hyperplasia and surface thrombogenicity are major factors in the
igh failure rate of synthetic small-diameter bypass grafts. Vascular endothelial
rowth factor is a potent stimulus for endothelial growth, and its provision in a fibrin
atrix coating at the luminal graft surface may hold a key to spontaneous graft
ndothelialization and improved graft patency.
ethods: Pigs underwent bilateral carotid artery interposition of expanded polytet-
afluoroethylene grafts either impregnated with fibrin (n  11)—engineered to
ocally release vascular endothelial growth factor121 (vascular endothelial growth
actor–fibrin; n  11)—or left uncoated (n  12). Graft patency was assessed by
uantitative carotid angiography followed by graft histomorphometry at the
-month experimental end point.
esults: Patency rates were not significantly different between study groups. Grafts
oated with fibrin or vascular endothelial growth factor–fibrin exhibited signifi-
antly increased angiographic narrowing at the proximal anastomosis (for both P 
05 vs uncoated) and no difference at the distal anastomosis and the grafts’ middle.
istological analysis showed 80% to 90% endothelial coverage and buildup of
ntima throughout the lengths of all grafts. Examination of the grafts’ midportion
evealed significantly enlarged neointimal layers of smooth muscle actin-positive
ells in grafts coated with vascular endothelial growth factor–fibrin (242  47
m2/) and fibrin (177  41 m2/), compared with uncoated grafts (131  39
m2/) (for both P  .05 vs uncoated). This thickening could not be explained by
nhanced inflammation or vessel wall angiogenesis, which were minimal at the
xperimental end point.
onclusions: Fibrin and vascular endothelial growth factor produced effects deleterious
o graft healing, by increasing the narrowing at proximal anastomosis and neointimal
rowth beyond that seen in uncoated grafts. It may reflect direct activation by exogenous
ascular endothelial growth factor of vascular smooth muscle cells.
ypass surgery is a common treatment for ischemic heart or limb disease, but
many patients requiring arterial replacements lack suitable autologous
small-diameter vein and/or arterial grafts for bypass surgery. Synthetic
rafts can be substituted for diseased arteries and function well as long as they are
f sufficiently large diameter and there exists high blood flow. In low-flow condi-
ions they are prone to thrombosis.1 The application of porous expanded polytetra-
uoroethylene (ePTFE) grafts, particularly at longer length and small internal
iameters (6 mm), is frequently associated with early thrombosis and late intimal
he Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 5 1163
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CSPyperplasia, leading to a high occlusion rate. Overall,
PTFE grafts exhibit inferior patency when compared with
utologous vein/artery grafts used as arterial substitutes.2
One difference between artery/vein grafts and prosthetic
rafts is the confluent endothelial lining, which is the only
onthrombogenic blood-compatible surface and which
lays an active role in maintaining vessel patency. The ideal
ynthetic blood vessel implant would therefore support the
rowth of functional endothelium lining an organized neo-
ntima with its resistance to thrombosis and protection from
xuberant neointima formation. Clinical in vitro endotheli-
lization of ePTFE grafts with mass-cultured autologous
ndothelial cells before implantation confirmed the expec-
ation that a confluent endothelium could prevent thrombo-
enic complications at the blood–material interface and
istinctly improve graft performance; indeed, clinical stud-
es have demonstrated that such grafts can function as well
s autologous vein grafts.3 However, this procedure is te-
ious and costly, and may be technically limited to practice
n speciality clinics. Ongoing research has therefore turned
oward development of spontaneously endothelializing syn-
hetic vessel implants4-6 by active recruitment of endothelial
ells across the anastomoses from the native vessel, trans-
ural ingrowth of capillaries, or recruitment of circulating
ndothelial progenitor cells. Surface treatments to increase
ndothelial cell adherence and retention on ePTFE grafts
nclude deposition of cell adhesion proteins (eg, collagen,7
aminin,8 and complex cell-derived extracellular matri-
es4,9). Surface coatings have also been considered to de-
iver angiogenic substances such as vascular endothelial
rowth factor (VEGF)10,11 or fibroblast growth factor(s)6
ith the idea to accelerate endothelialization while inhibit-
ng neointimal hyperplasia.
We recently introduced a scheme of covalent affixation
f VEGF in fibrin matrix that protects VEGF from washout
y flow.12,13 For that, we created a genetically engineered
ecombinant variant of VEGF121, 2PI1-8-VEGF121, that
ecomes crosslinked to fibrin during fibrin coagulation
hrough the transglutaminase activity of factor XIII. The
brin-bound 2PI1-8-VEGF121 can only be liberated by cell-
ecreted proteases, such as plasmin or matrix metallopro-
einases, produced at the surface of cells that contact or
nvade the fibrin matrix.14 In the present study, the unique
EGF retention-and-release property of such engineered
Abbreviations and Acronyms
ePTFE expanded polytetrafluoroethylene
SEM  scanning electron microscopy
TBS  tris-buffered saline
VEGF  vascular endothelial growth factorbrin matrix coating was tested for spontaneous endothelial m
164 The Journal of Thoracic and Cardiovascular Surgery ● Maoverage of surfaces of synthetic 4-mm ePTFE bypass
rafts that were interposed in pig carotid arteries.
aterials and Methods
raft Coating
tandard ePTFE grafts of 4-mm internal diameter with a through
orosity and an internodal distance of 30 m (provided by Dr P.
artakos, Atrium Medical Corporation, Hudson, NH) were cut to
cm lengths and freshly impregnated with fibrin under sterile
aminar flow conditions, typically approximately 24 hours before
urgery (Figure 1, A). The components used to form fibrin matrix
ith covalently affixed VEGF121 have been described.12-14 Before
oating, the grafts were placed into centrifuge tubes and immersed
n pure ethanol. To achieve complete wetting, all air was removed
rom the grafts by applying vacuum with a membrane vacuum
ump. Grafts were then immersed for 15 minutes under vacuum in
ris-buffered saline (TBS) to remove residual ethanol and then in
BS containing 2 National Institutes of Health units/mL of human
hrombin (Sigma, St Louis, Mo) and 2.5 mmol/L CaCl2. To form the
brin coating at the graft flow surface, 0.5 mL of TBS containing 10
g/mL human fibrinogen (plasminogen-free quality; Sigma) and 2
/mL factor XIII (provided by Baxter BioScienceAG, Vienna,
ustria) were injected with a 1-mL syringe through the throm-
in-impregnated ePTFE. VEGF-containing fibrin coatings were
ormed by admixture of 0.5 g/mL 2PI1-8-VEGF121 to the solu-
ion of fibrinogen and factor XIII. Immediately after fibrin poly-
erization, the ePTFE tubes were flushed with sterile TBS and
ept in TBS at 4°C until implantation.
rteriovenous Shunt Perfusion System
tability of the fibrin coating on ePTFE grafts under flow and acute
hrombogenicity were assessed in a porcine femorofemoral arte-
iovenous extracorporeal circuit as described previously.15 Perfu-
ion was performed for 30 minutes. A series of shunts was con-
tructed by connecting 5 cm graft segments through metallic
pacers. Each series of shunts consisted of fibrin, VEGF–fibrin,
nd bare control grafts randomly positioned along the shunt (n 4 for
ach group). As evaluation, confocal microscopy with Oregon
reen fluorescent fibrin staining (stability test of coating) and
canning electron microscopy (SEM) (thrombogenicity and cell
eposition test) were used.
urgical Pig Carotid Artery Replacement
he experimental protocol was approved by the Ethical Animal
ommittee of the University of Geneva and the Governmental
eterinary office of the State of Geneva (No. 31.1.1081/2139/II)
nd conducted in compliance with the “Guide for the Care and Use
f the Laboratory Animals” (National Research Council, Wash-
ngton, DC: National Academy Press; 1996). Seventeen Swiss
ouse swine aged 3 to 4 months (29  2 kg) were used in this
tudy. They were fasted the night before surgery and received
ormal food throughout the postoperative period. Bilateral carotid
rtery graft interposition was performed through a cervical midline
ncision. The carotid arteries were prepared and freed on a length
f approximately 8 to 10 cm by taking care to prevent vascular
pasm with externally applied papaverine solution. After proximal
nd distal clamping of the carotid artery, a segment of approxi-
ately 3 cm was excised in a beveled way. The prostheses were
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Plso beveled and trimmed to a length of 5 cm. Proximal and distal
nastomoses were performed with 7-0 polypropylene continuous
uture. The quality of surgery was evaluated with intraoperative
ransit time flow measurement and immediate postoperative selec-
ive carotid angiography that was quantified according to the
odified North American Symptomatic Carotid Endarterectomy
rial formula.16 Throughout the survival period, animals were fed
.5 g of aspirin daily until sacrifice at 1 month. After 1 week,
uplex examination was performed in a mask narcosis (isoflurane
%) after standard premedication. At the 1-month study end point,
control selective carotid angiography was first performed fol-
ABLE 1. Patency and stenosis rates (%) at proximal/dista
ollow-up
Patency Pro
ncoated (n  10) 7/10
ibrin coated (n  9) 7/9
EGF–fibrin coated (n  9) 7/9
ariance analysis* 0.996
ann–Whitney U test 0.008
0.008
0.132
umbers in bold represent significant differences at the level of P  0.05
Figure 1. A, Scanning electron micrographs of noncoa
venous shunt blood perfusion. B, SEM shows increased
and VEGF–fibrin-coated ePTFE surfaces compared w
arteriovenous shunt perfusion.arametric values, and Kruskal–Wallis test for nonmatched, nonparametric valu
The Journal of Thoracicowed by exposure of the grafts. After 10,000 units of intravenous
eparin, grafts were excised with 2 cm of native proximal and
istal carotid artery. They were then rinsed with saline followed by
% formaldehyde for fixation.
mmunohistochemistry and Scanning
lectron Microscopy
ormalin-fixed vessel graft explants were cut in half, opened
ongitudinally, and separated into 2 halves, 1 for SEM analysis and
embedded in paraffin for histomorphometry. Stainings were
erformed on deparaffinized sections with hematoxylin-eosin and
astomoses and at the middle of the graft after one-month
Stenosis (%)
anastomosis Midgraft Distal anastomosis
6 3 25 6 35  5
1 4 19 10 39  9
9 4 25 9 41  6
.034 0.523 0.798
ated vs fibrin)
ated vs VEGF)
vs VEGF)
F, Vascular endothelial growth factor. *Chi-square test for nonmatched,
and VEGF–fibrin-coated ePTFE surface before arterio-
elet deposition and microthrombus formation on fibrin
oncoated grafts after 30 minutes of extracorporeall an
ximal
3
5
4
0
(unco
(unco
(fibrin
. VEGted
plat
ith nes.
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Phe following antibodies: goat polyclonal anti-CD31 (PECAM;
anta Cruz sc-1506) for endothelial cells; mouse antihuman
mooth muscle actin (DAKO clone 1A4) for smooth muscle actin-
ositive cells; and MAC387 mouse anti-human macrophage L1
alprotectin (DAKO, M0747) for macrophage. Conventional pa-
hology stains were performed with Miller for elastin and Landrum
or fibrin.
istomorphometry
ntimal hyperplasia and endothelial coverage were determined
sing a Leitz Medilux (Leica, Nussloch, Germany) motorized
icroscope, a Sony 3CCD color video camera DCC9-930P, and
he software Leica Q-Win standard version Y2.3 for image anal-
sis. The intimal area was defined as the region between luminal
ndothelium and ePTFE graft surface and calculated per unit
ength (micrometer squared/micrometer). The percentage of lumi-
al graft surface neoendothelialization was expressed as the per-
entage of the total graft length. Neointimal and adventitial neo-
ngiogenesis in the neointima was quantified by counting the
umbers of CD31-positive vessels. Macrophage numbers in the
eointima were obtained by counting MAC387-positive cells. Ves-
el and macrophage counts are expressed as numbers per high
ower field (400) with n  10 per graft sample. The inner
urface morphology of the graft was examined by SEM (Philips
L20 SEM, Eindhoven, The Netherlands) at predefined locations,
ettings, and magnifications (20, 200, and 800 magnification).
tatistics
he results are expressed as mean values  standard error of the
ean. The Kruskal–Wallis test was used for variance analysis of
onmatched, nonparametric values between 3 groups. Thereafter,
ach group was compared with others using the Mann–Whitney U
est. Chi-square test was used to compare nonmatched, parametric
alues (Statistical Package for the Social Sciences version 11.5;
PSS Inc, Chicago, Ill).
esults
ibrin Coating Is Stable and Prone to Early
ell Deposition
fter 30 minutes of blood perfusion (arteriovenous shunt),
he Oregon green fibrin staining by confocal microscopy
as unchanged compared with unperfused grafts. Qualita-
ive examination of coated (fibrin, VEGF-fibrin) and bare
PTFE grafts by SEM showed increased cellular deposition
Figure 2. A, Graft histology at the experimental end po
ePTFE grafts coated with fibrin or VEGF–fibrin over nonc
portions. Immunohistochemistry with anti-CD31 for end
muscle cells (right), and hematoxylin-eosin (left). The
surface ultrastructure at the experimental end point by S
cells aligned in direction of flow. Sites of bare ePTFE
(left). VEGF–fibrin-coated graft with a confluent laye
photomicrographs of CD31-stained neointima (upper ro
differences in capillary counts among uncoated, fibrin-
study group, capillary formation was substantially higher in
The Journal of Thoracicnd microthrombus formation after arteriovenous shunt per-
usion (Figure 1, B). None of the shunted grafts occluded
uring the procedure.
nimal Follow-up After Surgery
eventeen pigs underwent bilateral carotid artery replace-
ent with ePTFE grafts coated with fibrin (n 11), VEGF–
brin (n  11), or left uncoated (n  12). Coated and
ncoated ePTFE grafts had the same surgical handling
haracteristics. Three animals developed postimplantation
omplications and were removed from the study. One ani-
al had to be sacrificed on postoperative day 3 because of
tridor and respiratory complications; autopsy showed both
rafts to be patent. One animal developed hind-limb isch-
mia after femoral artery occlusion secondary to angio-
raphic catheter introduction and was sacrificed on postop-
rative day 10; both grafts were angiographically patent.
ne pig was sacrificed on postoperative day 7 after angio-
raphic assessment of bilateral carotid artery occlusion as-
ociated with severe arteritis as assessed by histology.
ssessment of Early and Late Graft Patency
wenty-eight ePTFE implants, 9 coated with fibrin, 9
oated with VEGF–fibrin, and 10 left uncoated, were ana-
yzed for early and late graft patency. Intraoperative and
mmediately postoperative assessment of the surgical qual-
ty with transit time blood flow measurements and quanti-
ative carotid angiography showed adequate graft perfusion
nd similar flow values in all 3 experimental groups and no
ignificant differences in the extent of surgery-induced nar-
owing at the proximal and distal anastomoses. One-week
ollow-up by duplex measurement showed 3 of the 28
rafts, 1 in each study group, occluded; the 1-month follow
p showed 2 additional graft occlusions in the uncoated
tudy group and 1 additional graft occlusion in the fibrin and
EGF-fibrin study groups. Table 1 illustrates the quantita-
ive angiography data at 1 month; 21 of 28 grafts, 7 in each
tudy group, remained patent. Fibrin- and VEGF–fibrin-
oated ePTFE grafts showed significantly increased narrow-
ng at the proximal anastomosis, namely, 51%  4% and
9%  4% (for both P  .05 vs uncoated) compared with
month, shows an increase of neointima formation on
d ePTFE. The pictures are taken from the grafts’ middle
ial cells (middle), anti-smooth muscle actin for smooth
t-neointimal border (arrows). B, Examination of graft
showed most parts lined by densely grown endothelial
ace were occasionally observed in noncoated grafts
aligned endothelial cells (right). C, Representative
nd adventitia (lower row). There were no significant
d, or VEGF–fibrin-coated grafts (see Table 3). In everyint, 1
oate
othel
graf
EM
surf
r of
w) a
coateadventitia than in neointima. IH, intimal hyperplasia.
and Cardiovascular Surgery ● Volume 133, Number 5 1167
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CSPncoated (36%  3%), and no difference at the distal
nastomosis and the grafts’ middle.
ibrin and Vascular Endothelial Growth Factor
ncrease Neointimal Thickening
ross histology at the 1-month experimental end point showed
eointimal thickening related to surgical trauma and local
nflammatory response at the grafts’ proximal and distal anas-
omosis sites. Hematoxylin-eosin staining showed buildup of
eointima along the entire luminal surface of ePTFE grafts.
andrum staining for fibrin remnants was negative, indicating
omplete remodeling of fibrin matrix into new tissue (not
hown). In both coated and uncoated conditions, the size of
eointima decreased toward the grafts’ midregions. Grafts
odified by fibrin and VEGF-fibrin elicited a significantly
nlarged smooth muscle actin-positive neointimal layer com-
ared with uncoated grafts in the following order: VEGF–
brin  fibrin  uncoated (Figure 2; Table 2). Histomorpho-
ABLE 2. Morphometric analysis of intimal hyperplasia and
olytetrafluoroethylene grafts
Uncoated
(n  7) Fibrin (n 
ntimal hyperplasia (m2/()
Whole graft 167 35 210  31
Anastomoses (proximal  distal) 241 36 356  47
Midgraft 131 39 177  41
eo-endotelial coverage (%)
Whole graft 80 4 82  3
Anastomoses (proximal  distal) 91 3 91  3
Midgraft 75 5 83  4
EGF, Vascular endothelial growth factor. Values are given as mean  s
ABLE 3. Capillary and macrophage counts in neointima a
oethylene grafts at the one-month experimental end poin
Uncoated
acrophage count in intima 25 1.5
apillary count in intima 2.7 1.5
apillary count in adventitia 97.0 2.0EGF, Vascular endothelial growth factor. Four grafts of each study group were
168 The Journal of Thoracic and Cardiovascular Surgery ● Maetric evaluation of the intimal area by computer-assisted
lanimetry determined 242  47 m2/ for VEGF–fibrin-
oated grafts (significant vs uncoated, P  .005), 177  41
m2/ for fibrin-coated grafts (significant vs uncoated, P 
012), and 131  39 m2/ for uncoated grafts (Table 2). The
ncorporation of exogenous VEGF into fibrin tended to result
n enhanced thickening compared with fibrin alone; however,
his effect was not significant. In all study groups, wide areas
f the neointima were lined at the luminal surface with CD31-
ositive endothelial cells (Figure 2). Endothelialization of
EGF-fibrin-coated ePTFE grafts (90%  3%) was slightly,
et insignificantly, enhanced versus fibrin-coated (82% 4%)
r uncoated (80%  4%) grafts (Table 2). CD31-stainings
howed neointima to be essentially free of capillaries (Table 3;
igure 2). However, there was a high number of capillaries
resent in the adventitia. Further, staining for elastin fibers in
he graft wall was negative (not shown). Examination of graft
-endothelial coverage of coated and noncoated expanded
VEGF–fibrin
(n  7)
Kruskal–Wallis
test Mann–Whitney U test
267 39 0.031 0.132 (uncoated vs fibrin)
0.008 (uncoated vs VEGF)
0.307 (fibrin vs VEGF)
358 34 0.026 0.060 (uncoated vs fibrin)
0.008 (uncoated vs VEGF)
0.917 (fibrin vs VEGF)
242 47 0.007 0.012 (uncoated vs fibrin)
0.005 (uncoated vs VEGF)
0.565 (fibrin vs VEGF)
90  3 0.172 0.911 (uncoated vs fibrin)
0.152 (uncoated vs VEGF)
0.071 (fibrin vs VEGF)
94  2 0.764 0.728 (uncoated vs fibrin)
0.458 (uncoated vs VEGF)
0.764 (fibrin vs VEGF)
89  3 0.254 0.451 (uncoated vs fibrin)
0.109 (uncoated vs VEGF)
0.346 (fibrin vs VEGF)
rd error.
dventitia in coated and uncoated expanded polytetrafluo-
ibrin VEGF-fibrin Kruskal–Wallis test
 3.5 22 2.5 0.981
 1.1 7.7 3.8 0.542
 11.8 120.2 16.3 0.368neo
7)nd a
t
F
19
3.2
104.7examined. There was no significant difference between the study groups.
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Purface ultrastructure by SEM (Figure 2) showed most parts
ined by densely grown endothelial cells aligned in the direc-
ion of flow; sites of bare ePTFE surface were occasionally
bserved in uncoated grafts. VEGF and fibrin could act as
hemoattractant and adhesion substrate for infiltrating mono-
ytes, respectively, which in turn could activate smooth muscle
ells by their secretion of cytokines and growth factors. How-
ver, our determination by MAC staining showed few macro-
hages in the neointima and no difference between the study
roups (Table 3).
iscussion
he principal findings of this study were that impregnation
f ePTFE graft surface with a slow-release fibrin coating for
EGF added little to the endothelialization rate but pro-
uced effects deleterious to graft healing beyond that seen
n uncoated grafts: (1) increased angiographic narrowing at
he proximal anastomosis and (2) increased neointimal
hickening, especially when VEGF was present. Although
he specific mechanisms underlying these adverse effects
re not clear, the untoward role of VEGF deserves attention
ecause it may be relevant for approaches to endothelial
essel regeneration after vessel injury in general.
Experimental studies of acute intraluminal arterial injury
ave led to the notion that the degree of reendothelialization
nversely correlates with the thickness of the neointima.
xogenous VEGF activities, delivered as protein or gene,
howed positive results for arterial healing through its ac-
eleration of reendothelialization and attenuation of vascular
mooth muscle cells after experimentally induced endothelial
njury.17-19 Therefore, we have looked at VEGF-releasing sub -
trate coatings to promote endothelial growth without pro-
oking smooth muscle cell proliferation on prosthetic graft
urfaces. In our experimental model, this strategy showed
ittle effect for enhancing endothelial coverage over the
ynthetic graft surface, at least at the 1-month time point.
his modest effect of exogenous VEGF for endothelial
rowth may be specific for this experimental model or the
osage of VEGF. It is also possible that VEGF activity per
e may not be as important for endothelialization as as-
umed. In support for this notion, blockade of endogenous
EGF signaling after balloon-induced endothelial denuda-
ion did not impair endothelial regeneration.20
Impregnation with fibrin alone enhanced neointimal
rowth beyond that measured in uncoated grafts. Fibrin matrix
n the form of the clinically approved plasma cryoprecipitate
fibrin glue” has been successfully used for ePTFE graft treat-
ent in clinical ex vivo endothelialization approaches with
ass-cultured autologous endothelial cells,21 as well as in
reclinical in vivo endothelialization approaches.6 Work by
arge and colleagues22 showed ePTFE grafts precoated with
brin glue to be less prone to platelet deposition compared
ith whole blood–preclotted ePTFE. Potentially, the neointi- e
The Journal of Thoracical thickening response observed in our experiments could
ave been triggered at the early implantation stage through
brin engagement of platelets or inflammatory cells, such as
eukocytes or monocytes, through integrins II3 and M2,
espectively.23 Platelets and monocytes secrete multiple fac-
ors, for example, platelet-derived growth factor, that activate
mooth muscle cell.20 Our inspection by SEM revealed in-
reased thrombus formation on fibrin-coated ePTFE grafts
ompared with uncoated specimen during a 30-minute perfu-
ion period in the arteriovenous shunt test (Figure 1, B). The
hrombin component used to form the fibrin coating on the
PTFE surface could activate platelets. Although the fibrin-
mpregnated grafts were washed before implantation, formally,
e cannot exclude that early thrombus formation observed
uring shunt perfusion resulted from residual thrombin on
brin-coated ePTFE grafts. At the 1-month experimental end
oint, the fibrin coatings were found completely remodeled
nto neointima, and approximately 80% to 90% of the ePTFE
raft luminal surfaces were covered with endothelium (Table
), without signs of thrombus (Figure 2).
Incorporation of VEGF into fibrin tended to further ac-
entuate neointimal thickening. A dual effect of VEGF for
nhancing the endothelialization rate of ePTFE grafts, but at
he same time neointimal hyperplasia, was recently found in
 rat abdominal artery interposition model.11 This indicates
general, relevant phenomenon of VEGF for neointimal
hickening during synthetic graft healing. Notably, the ex-
erimental systems of both studies differed in many details,
hat is, in the animal model (pig vs rat), surgical location
carotid vs abdominal artery), graft diameter/length (5 cm/4
m vs 1 cm/2 mm), coating material (clinical relevant fibrin
atrix vs experimental growth factor-reduced Matrigel [BD
iosciences, Franklin Lakes, NJ]), mechanisms of VEGF
elease (cell controlled vs passive release), and data acqui-
ition (angiography and histology vs histology alone). From
he literature, the contribution of VEGF to vessel wall
ealing after arterial injury has remained unclear and con-
roversial.24 Accumulating evidence suggests that the over-
ll effect of VEGF signaling during vessel wall healing may
ot be exclusively inhibitory for vascular smooth muscle
ell growth as commonly assumed. Studies of arterial heal-
ng after experimental injury have indicated that exuberant
mooth muscle growth could be mediated by direct activa-
ion of VEGF of smooth muscle cell migration25-27 or
ndirectly through VEGF-mediated vessel wall angiogene-
is27 and recruitment of inflammatory cells such as mono-
ytes.20 Our graft histology at 1 month showed few capil-
aries in the neointima and counts of MAC-positive cells to
e low and indifferent between study groups. This suggests
hat neoangiogenesis and monocytes were unlikely causes
or driving smooth muscle cell growth in this system in the
ater experimental phase; however, we cannot exclude those
ffects in the early phases of the experiment.
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CSPAlthough our study in pigs found high spontaneous en-
othelial coverage of approximately 80% in bare and fibrin-
oated ePTFE grafts, and insignificant increase in the con-
ition in which VEGF was present, bare ePTFE grafts in the
at model by Randone and colleagues11 exhibited a low
pontaneous endothelial coverage of approximately 20%,
hich was substantially increased to approximately 35%
nd 50% on coating with Matrigel alone or Matrigel plus
EGF, respectively. This shows great biological disparity
etween species in their capacities to spontaneously endo-
helialize synthetic grafts that can only be determined
hrough the experiment.
Anastomotic ingrowth constitutes the most likely origin
f endothelial and smooth muscle cells forming the neoin-
ima on our fibrin-impregnated ePTFE. Possibly, bone marrow-
erived circulating progenitor cells could also contribute to
eointima hyperplasia by giving rise to smooth muscle cells
s after arterial injury.28 Although the chemokine properties
f VEGF for mobilizing endothelial progenitor cells are
ell established,29 a similar effect of VEGF for recruiting
rogenitors of smooth muscle cells is yet unknown.
The authors thank Stephanie Zimmerli, Sylvie Roulet, Manual
osta, Jean-Luc Munier, and Myriam Vitali for assistance during
urgery; Unn Lutzen, Catherine Biton, Marie Claude Reymond,
nd Professor Ivo Krejci for their expertise in morphology and
icroscopy; Dr Nadia Popova for the postoperative ultrasound
xaminations; Dr Klaus Marquart, Dr Urs Ziegler, and Professor
roscurth from the University of Zurich for expert help with
lectron microscopy and histology.
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